Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Eiken Chemical Co., Ltd. ( (JP:4549) ).
Eiken Chemical reported fiscal 2026 net sales of ¥41.9 billion, up 3.4% year on year, with operating profit down 2.7% to ¥2.9 billion and ordinary profit falling 11.1%. Profit attributable to owners of the parent, however, jumped 66.5% to ¥3.7 billion, aided by a lower share count, pushing basic earnings per share to ¥112.52 and lifting comprehensive income by 83.5%.
The company maintained a solid financial base with total assets of ¥62.7 billion, an equity ratio of 70.1%, and year-end cash and cash equivalents of ¥7.9 billion. It raised the annual dividend to ¥58 per share, implying a 51.5% payout ratio, and guided for flat sales but a modest rebound in operating profit in fiscal 2027, even as it forecasts a sharp decline in net profit, signaling margin and earnings pressure despite ongoing shareholder returns.
More about Eiken Chemical Co., Ltd.
Eiken Chemical Co., Ltd. is a Japan-based diagnostics company listed on the Tokyo Stock Exchange, specializing in clinical testing reagents and related medical products. The company targets hospital, laboratory, and public health markets, focusing on stable domestic demand and selective overseas operations in the in vitro diagnostics sector.
Average Trading Volume: 176,271
Technical Sentiment Signal: Buy
Current Market Cap: Yen100.6B
Find detailed analytics on 4549 stock on TipRanks’ Stock Analysis page.